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Identification of p38b as a Therapeutic Target for the
Treatment of Se´zary Syndrome
Meghan Bliss-Moreau1, Cristian Coarfa2, Preethi H. Gunaratne3, Joan Guitart4,5, Nancy L. Krett1 and
Steven T. Rosen1,5,6
Cutaneous T-cell lymphomas (CTCLs) represent a group of hematopoietic malignancies that home to the skin and
have no known molecular basis for disease pathogenesis. Se´zary syndrome (SS) is the leukemic variant of CTCL.
Currently, CTCL is incurable, highlighting the need for new therapeutic modalities. We have previously observed
that combined small-molecule inhibition of protein kinase C-b (PKCb) and glycogen synthase kinase 3 (GSK3)
causes synergistic apoptosis in CTCL cell lines and patient cells. Through microarray analysis of a SS cell line, we
surveyed global gene expression following combined PKCb–GSK3 treatment to elucidate therapeutic targets
responsible for cell death. Clinically relevant targets were defined as genes differentially expressed in SS patients
that were modulated by combination-drug treatment of SS cells. Gene set enrichment analysis uncovered
candidate genes enriched for an immune-cell signature, specifically the T-cell receptor and mitogen-activated
protein kinase signaling pathways. Further analysis identified p38 as a potential therapeutic target that is
overexpressed in SS patients and decreased by synergistic-inhibitor treatment. This target was verified through
small-molecule inhibition of p38, leading to cell death in both SS cell lines and patient cells. These data establish
p38 as a SS biomarker and a potential therapeutic target for the treatment of CTCL.
Journal of Investigative Dermatology (2015) 135, 599–608; doi:10.1038/jid.2014.367; published online 25 September 2014
INTRODUCTION
Cutaneous T-cell lymphomas (CTCLs) represent a heteroge-
neous group of hematopoietic malignancies that account for
5–10% of non-Hodgkin lymphomas. Mycosis fungoides (MF)
and Se´zary syndrome (SS) are the most common CTCL
subtypes, and, they are characterized by the infiltration of
the skin by malignant clonal CD4þ lymphocytes that possess
a mature memory T-cell phenotype (Rosen et al., 2008).
Patients with MF, the more indolent subtype, present with
patch, plaque, and/or tumors of the skin that progress through
defined stages (Girardi et al., 2004). The leukemic variant, SS,
is aggressive and characterized by generalized erythroderma
and circulating malignant T cells (Se´zary cells; Querfeld
et al., 2003).
Little is understood about the pathogenesis of CTCL. To
date, no clear molecular drivers of disease progression
have been identified. Broad screening approaches using
CTCL models have detected altered microRNA expression
levels (Ballabio et al., 2010), modulated gene expre-
ssion levels (Shin et al., 2007; Wang et al., 2011), single-
nucleotide polymorphisms (Caprini et al., 2009), and
low frequency genomic mutations (Kiessling et al., 2011;
Lamprecht et al., 2012; Vaque´ et al., 2014). Despite these
findings, no curative treatments for CTCL have been found and
applied in clinic.
Previous work in our laboratory demonstrated that inhibit-
ing the protein kinase C-b (PKCb) pathway in CTCL in vitro
with the small-molecule Enzastaurin (Enz) increases apoptosis
(Querfeld et al., 2006). However, during the clinical trial, Enz
only demonstrated modest biological activity and efficacy
(Querfeld et al., 2011). Using Enz as a platform for further
mechanistic discovery and possible combination therapy in
clinic, we then established that simultaneous inhibition of the
PKCb and glycogen synthase kinase-3 (GSK3) pathways
synergistically increased apoptosis in both MF and SS cell
lines and SS patient samples (Rovedo et al., 2011). Further
investigations determined that combined treatment increased
b-catenin protein levels and that b-catenin downstream
transcription activation negatively impacted CTCL viability
(Rovedo et al., 2011). However, expression of b-catenin
alone was not sufficient to induce CTCL apoptosis (data
not published). These data indicate there are additional
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mechanisms of cell death stimulated by the synergistic
inhibition of PKC and GSK3.
In this report, we use a combination of chemical
biology perturbations and expression profiling to elucidate
global mechanisms underlying combined PKCb and GSK3
treatment to identify therapeutic targets for the treatment of SS.
In doing so, we establish a previously unreported mechanism
driving SS proliferation. Our data demonstrate that the
synergistic inhibition of PKCb and GSK3 pathways in SS cell
lines enriches for an immune-cell signature, specifically the
TCR signaling pathway. Further target identification charac-
terizes p38 as one driver of SS growth. Inhibition of this
protein by targeted small-molecule inhibitors induces apopto-
sis in both cell lines and patient samples. We therefore
demonstrate p38 as a potential SS biomarker and thera-
peutic target.
RESULTS
Gene set enrichment analysis of PKCb/GSK3 combination
treatment of SS cell lines and patient samples uncovered TCR
signaling and p38a/b MAPK pathways
Previous data from our laboratory indicate that combined
inhibition of PKCb and GSK3 with the small molecules Enz
and AR-A014418 (ARA) synergistically induces apoptosis in
CTCL cell lines and patient samples (Rovedo et al., 2011). To
identify drivers of this cytotoxic phenotype and genes poten-
tially responsible for CTCL growth and malignancy, we assayed
drug-treatment–induced changes in global gene expression
using a microarray approach. To prevent saturation with end-
stage cell death genes, we conducted the array experiments at
day 3 as opposed to day 5 in which we observe maximal cell
death (Rovedo et al., 2011). Hut78 cells, a well-characterized
SS cell line (Gazdar et al., 1980), were treated with either Enz,
ARA, a combination of both small molecules (EnzþARA), or
DMSO vehicle. Cell death by Annexin V staining, gene
expression of previously established modulated genes AXIN2
and BCL2L1, and total b-catenin expression by immunoblot
were measured to confirm that drug treatments were effective
before purifying RNA for microarray analysis (Supplementary
Figure S1 online).
To identify genes modulated by EnzþARA that drive
synergistic killing of Hut78 cells, we compared gene expres-
sion of all treatments against the vehicle treatment and
performed comparisons between the transcriptome responses
of each treatment group. A total of 2,610 genes were signifi-
cantly differentially expressed across all treatments, with 519
upregulated and 1,288 downregulated by EnzþARA (fold
change (FC) 42, Po0.05). The Venn diagram shows a greater
overlap between ARA and combination-drug treatment than
between Enz and combination-drug treatment (Figure 1a). This
observation was reinforced by hierarchical clustering using
Pearson’s correlation coefficient (Figure 1b).
Gene set enrichment analysis was performed using the
combination-drug treatment signature to identify signaling
pathways (qp0.05) that may be responsible for inducing SS
cell death. Immune-related pathways and immune-cell signa-
tures were identified as enriched by this analysis (Figure 1c
and Supplementary Table S1 online). Pathways involved with
IFN signaling were also significantly enriched. These findings
are consistent with reports that H9 and Hut78 cells are
sensitive to IFN (Sangfelt et al., 1997; Sun et al., 1998) and
that IFN-a-resistant Hut78 cells have different transcriptional
response profiles compared with sensitive cells (Tracey et al.,
2004). In addition, CTCL patients benefit from IFN treatment
(Bloom et al., 2012). EnzþARA treatment also enriched
for genes in the TCR signaling pathway (Figure 1c). Other
signaling pathways identified by gene set enrichment analysis,
such as the p38a/b, mitogen-activated protein kinase (MAPK),
phosphoinositide 3-kinase, and SHP2 signaling pathways,
have members that are downstream and/or cross talk with
the TCR signaling pathway. Enrichment of nuclear b-catenin
signaling confirmed our previous observations that combined
drug treatment leads to increased b-catenin transcriptional
activity (Rovedo et al., 2011).
The combination-drug treatment enriched for the TCR
signaling pathway and for downstream signaling members of
the p38a/b MAPK pathway. When comparing FC for each
treatment, several of these shared genes showed potential
synergistic behavior (Supplementary Figure S2 online). To
validate our microarray data, standard 5-day compound
treatment was performed and cell death confirmed by poly
ADP ribose polymerase cleavage and Annexin V staining
(Supplementary Figure S3a–c online). Drug-induced expres-
sion of selected genes in the b-catenin and TCR signaling
pathways was measured by quantitative real-time reverse-
transcriptase–PCR to validate the observed changes in gene
expression identified in the microarray (Supplementary Figure
S3d online). These data confirm our microarray findings and
highlight the potential importance of TCR signaling in SS.
To identify candidate genes that may have therapeutic
importance and to further explore the clinical relevance of
our drug-treatment data set, we interrogated the gene expres-
sion profile of a set of SS patients (GSE17602; Caprini et al.,
2009) normalized to normal CD4þ T cells (GSE8835; Go¨rgu¨n
et al., 2005) using the methods previously described in this
paper. Hierarchical clustering was performed for the 3,354
differentially modulated genes in SS patients. A total of
1,696 genes were upregulated, whereas 1,658 genes were
downregulated in patients (Figure 2a). Gene set enrichment
analysis was performed, and, of the top 100 pathways with
significant enrichment in our patient data set (qo0.05),
17 pathways were shared with the combination-drug treat-
ment signature (Figure 2b and Supplementary Table S2
online). TCR and MAPK signaling pathways were enriched
in both data sets (graphical representation of genes modulated,
Supplementary Figure S4 online). To further refine our candi-
date genes to those with clinical relevance for target identi-
fication, we selected genes with expression negatively correlated
between patients and drug-treated cell lines. Eighty-nine genes
were simultaneously upregulated in SS patients and down-
regulated by combination-drug treatment; 34 genes were
downregulated in SS patients and upregulated by EnzþARA
treatment (Figure 2c and Supplementary Tables S3 and S4
online). Of the shared genes, several were associated with
the TCR pathway and immune system signaling. In parti-
cular, MAPK11 (p38b) showed significant correlation with
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overexpression in SS patients and downregulation by
combination-drug treatment (SS, FC¼3.5473; EnzþARA,
FC¼0.4991).
Combined PKCb/GSK3 inhibition modulates MAPK-p38 isoform
expression in SS models
p38-MAPK signaling converts numerous extracellular signals
into a spectrum of cellular responses (such as stimulation of
proliferation or apoptosis) through changes in transcriptional
regulation, post-translational modifications, or tissue-specific
expression of the four p38 isoforms (Cuenda and Rousseau,
2007; Cuadrado and Nebreda, 2010). In the healthy T-cell
setting, reports document that p38a is highly expressed and
p38b and p38d to lesser extents (Wang et al., 1997; Hale
et al., 1999). p38g and p38d expressions are largely restricted
to non-hematopoietic tissues (Li et al., 1996; Wang et al.,
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Figure 1. Combined small-molecule microarray analysis and results. Global gene expression analysis was performed on Hut78 cells treated for 3 days with
Enzastaurin (Enz), AR-A014418 (ARA), and EnzþARA. DMSO (vehicle) or no treatment cells served as controls. Four serial replicates were collected. (a) Venn
diagrams of up- and downregulated genes. (b) Hierarchical clustering of the 2,610 differentially regulated genes using Pearson’s correlation coefficient.
(c) Combined EnzþARA treatment enriches for an immune-cell signature. Gene set enrichment analysis (GSEA) was performed on combination-treatment gene
signature (1,807 total). TCR signaling, downstream p38a/b signaling, and nuclear b-catenin signaling pathways were enriched post EnzþARA treatment.
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1997). Surprisingly, all four p38 isoforms were endogenously
expressed in SS cell lines with high mRNA and protein
expression levels (Figure 3a and b and Supplementary Figure
S5 online), as reported in few other malignancies (Pramanik
et al., 2003; O’Callaghan et al., 2013). Using quantitative
real-time reverse-transcriptase–PCR, we confirmed our drug
treatment microarray data and determined that MAPK11
(p38b) was significantly downregulated following EnzþARA
treatment in both H9 and Hut78 cell lines after 5-day
treatment (Figure 3a). MAPK12 (p38g) gene and protein
expression was also significantly downregulated after drug
treatment in cell lines (Figure 3a and b). p38d (MAPK13)
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protein expression in Hut78 cells post EnzþARA treatment
was modestly reduced by 28.86% (P¼0.0287; Supplementary
Figure S5 online). In contrast, p38b was decreased by 88.83%
(P¼ 0.0054) upon inhibitor treatment.
Similar to SS cell lines, primary cells from SS patients had
high endogenous gene and protein expression of p38a, p38b,
and p38d (Figure 3c and d and Supplementary Figure 5e
online). However, p38g protein was either undetectable or
expressed at very low levels in the five SS patients examined
(Figure 3d and Supplementary Figure 5e online). Variable
expression of p38g in healthy volunteers contradicted previously
published observations (Hale et al., 1999). Importantly, trends
in MAPK11/p38b expression reproduced observations from
published patient sample microarray data, negative correlation
data, and cell line observations with statistical significance
(Figure 3c and d and Supplementary Table S3 online). These
data are consistent with the hypothesis that overexpression of
MAPK11/p38b in SS may be an important biomarker and
possible target for small-molecule therapy.
Inhibition of p38 is sufficient to induce apoptosis in SS cell lines
To test whether inhibition of MAPK11/p38b is sufficient to
induce SS cell death, we used small interfering RNA to knock
down (KD) MAPK11 in our cell lines. Although we saw
complete KD of MAPK11 in both Hut78 and H9 cells, we
did not detect an increase in apoptosis by Annexin V staining
(data not shown). p38 isoforms have approximately 60%
amino acid sequence homology and share the same putative
duel phosphorylation motif in the kinase domain (Jiang et al.,
1996; Lechner et al., 1996; Wang et al., 1997). Functional
redundancy of isoforms has been demonstrated by the ability
of individual isoforms to rescue loss of other p38 isoform
function (Sabio et al., 2005; Okada et al., 2007). This may
explain the lack of cell death in the face of individual p38
isoform KD in SS cells. Note, simultaneous KD of all four p38
isoforms did not cause robust KD across all isoforms (data not
shown). These experimental limitations led us to employ other
methodologies to elucidate the importance of p38-MAPK
signaling in SS.
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Figure 3. Se´zary syndrome (SS) cell lines and patient samples express all p38 isoforms. p38b (mitogen-activated protein kinase 11 (MAPK11)) is differentially
regulated by small-molecule inhibitor treatment. (a,b) H9 and Hut78 cells were treated with Enzastaurin (Enz) and AR-A014418 (ARA) as previously described,
n¼ 3. (a) MAPK14, MAPK11, MAPK12, and MAPK13 mRNA expression measured by quantitative real-time reverse-transcriptase–PCR (qRT-PCR). (b) p38 isoform
protein expression, normalized to a-tubulin, was measured by immunoblot. Representative immunoblot images of three replicates (quantification, Supplementary
Figure 5 online). (c,d) Endogenous cutaneous T-cell lymphoma (CTCL) patient and healthy donor cell samples. (c) MAPK isoform mRNA expression measured by
qRT-PCR, normalized to housekeeping genes, and normalized to donor cells. (d) Quantitative representation of p38 isoform immunoblots. Protein expression
normalized to loading control (a-tubulin) expression and then normalized to healthy volunteers. H9/Hut78 cells as positive controls.
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There are numerous MAPK inhibitors that target p38 iso-
forms with varying efficacies; many have multiple known off-
target effects. We chose a panel of three p38 inhibitors with
established in vitro kinase properties and in vivo physiological
functions. We treated H9 and Hut78 cells with increasing
concentrations of either SB202190 (SB202), SB203580
(SB203), or BIRB796 (BIRB) for 5 days. Inhibition of p38
induced apoptosis in both cell lines, with a more robust inhibi-
tion observed in H9 cells (Figure 4a and Supplementary Figure
S6 online). Both cell lines were more sensitive to SB202, an
inhibitor documented to be p38b specific in vivo (Nemoto
et al., 1998). Greater amplitude of response was observed with
both SB202 and SB203 inhibitors compared with BIRB
treatment, perhaps due to the off-target inhibition of other
kinases, such as GSK3. We established GSK3 as a driver of SS
death in our microarray data (Figure 1). To a lesser extent, H9
and Hut78 cells were sensitive to BIRB (Figure 4a–c).
BIRB-induced apoptosis is through a p38-specific mechanism
To confirm the p38-specific mechanism of cell death by BIRB
in our SS tissue-culture models, we co-treated H9 and Hut78
cells with EnzþARA over an increasing dose range of BIRB.
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Hut78 cells were treated with increasing concentrations of either SB202, SB203, or BIRB. Apoptosis was measured by flow cytometry, n¼ 3. (b,c) H9 and Hut78
cells were cultured with either Enzastaurin (Enz)þAR-A014418 (ARA) plus BIRB or increasing concentrations of BIRB alone for 5 days. (b–d) Apoptosis was
measured by Annexin V staining, n¼ 3. Total cell death is represented as a fold change (FC) normalized to DMSO, in the absence of BIRB treatment. Comparisons
were made between cells treated with BIRB alone and those treated with BIRB in the presence of EnzþARA. (b) H9, (c) Hut78, (d), raw cell death (Annexin V–
positive cells), and no BIRB treatment.
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We have established that EnzþARA treatment markedly
reduces p38 protein isoform expression (Figure 3b), while
inducing cell death. Lacking the p38 substrate, as a result of
EnzþARA treatment, BIRB should have no additional effect
on SS cell viability. The concentration range of BIRB used
caused cell death when administered as a mono-therapy in H9
cells (Figure 4b, solid line). There were significant correlations
between BIRB concentration and mean normalized cell death
for H9 samples treated with EnzþARA and H9 samples not
treated with EnzþARA (no treatment: r¼ 0.925, Po0.0001;
treatment: r¼ 0.598, P¼ 0.009), indicating that in both
samples increasing concentrations of BIRB were related to
increased cell death. Importantly, the correlation coefficients
differed significantly, z¼ 2.55, P¼0.011, indicating that the
effect of BIRB concentration was significantly greater for
samples that were not treated with EnzþARA. Therefore,
although treatment with EnzþARA causes significant cell
death compared with cells with no treatment (Figure 4d), the
addition of BIRB in increasing concentrations did not induce
significant additional apoptosis in H9 cells with EnzþARA
(Figure 4b, dashed line). These trends were recapitulated in
Hut78 cells, although not statistically significant (Figure 4c).
Thus, we conclude that the cell death induced by these
inhibitors was likely through a p38 mechanism.
Inhibition of p38 is sufficient to induce cell death in primary SS
patient samples
To validate our in vitro observations and determine the
clinical relevance of our small-molecule findings, we treated
SS patient cells with p38 inhibitors ex vivo. Literature suggests
that isolation procedures for blood cells can affect the
activation status of the p38-MAPK pathway (Branger et al.,
2002). Therefore, we used peripheral blood mononuclear cells
(PBMCs) from both patients and healthy volunteers rather than
enriching for T cells. After 5 days in culture, vehicle-treated SS
patient PBMCs showed a modest but not statistically signifi-
cant increase in baseline cell death (Figure 5 and Supplemen-
tary Figure S7 online). Apoptosis measured by Annexin V
staining was significantly enhanced following low-dose
(10–25mM) SB202 treatment, in patient samples compared
with healthy volunteers (Figure 5a). SB203 treatment had
significant effects on patient PBMC death across the full dose
range tested (Figure 5b). However, treatment with BIRB, the
pan p38 inhibitor, only caused a significant increase in
apoptosis in SS patient cells at the lowest dose assayed
(10mM; Figure 5c). Apoptotic cell death was confirmed by
the measurement of cleaved caspase staining (Supplementary
Figures S7 and S8 online). Overall, these data parallel our
observations made in cell lines (Figure 4a). We conclude that
p38 may be a therapeutic target in SS, and the inhibition of
p38 using targeted small molecules may provide clinical
benefit for SS patients.
DISCUSSION
Development of targeted therapies for CTCL requires identifi-
cation of underlying molecular mechanisms for the disease.
Here we identified MAPK11/p38b as a possible driver of SS
pathogenesis through integration of global gene expression
data sets of drug-treated SS cells and primary SS patient
samples. Significant upregulation of both MAPK11 mRNA
expression and p38b protein expression in SS cell lines and SS
patient samples compared with healthy donor samples identi-
fied that MAPK11/p38b is a potential driver and/or biomarker
for SS.
To demonstrate that inhibition of p38 is sufficient to induce
apoptosis in SS cell lines and patient samples, we used a panel
of p38 inhibitors. We selected three p38 small molecules that
were recommended for use, in sequence, to study the
physiological roles of p38 (Bain et al., 2007). The pryindinyl
imidazoles SB202190 (Lee et al., 1994) and SB203580
(Cuenda et al., 1995) are strong inhibitors of only p38a and
p38b. However, data from in vitro ATP kinase assays document
that both small molecules have known off-target inhibitory
effects on GSK3b, CK1d, RIP2, and GAK (Bain et al., 2007).
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Figure 5. Importance of p38 signaling in primary Se´zary syndrome (SS)
patient samples. (a–c) Peripheral blood mononuclear cells (PBMCs) were
harvested from SS patients (n¼ 3) and healthy volunteers (n¼ 5) and treated
with increasing concentrations of either SB202, SB203, or BIRB. Cell death was
assessed by flow cytometry. Annexin V staining, positive stained cells
quantified as percentage total PBMCs (for gating examples see Supplementary
Figure S7 online). (a) SB202, (b) SB203, and (c) BIRB.
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In an in vivo setting, SB202 was demonstrated to induce death
through preferential inhibition of p38b over p38a (Nemoto
et al., 1998). BIRB, a diaryl urea compound that inhibits all
four isoforms of p38, lacks the off-target interactions of SB202
and SB203 (Pargellis et al., 2002; Regan et al., 2002; Bain
et al., 2007). These defined in vitro kinases and in vivo
physiological properties clearly explain the results observed in
our drug-treatment experiments.
In order to identify the driver(s) of MAPK11 overexpression
in SS primary cells, we analyzed gene expression data from SS
patient samples and found a clear enrichment of both TCR and
MAPK signaling pathways (Figure 2b and Supplementary
Figure S4 online). Following combination PKCb and GSK3
inhibitor treatment, we demonstrated modulation of other TCR
genes such as CD4, ICOS, and LAT (Supplementary Figure S3
online), supporting the hypothesis that TCR signaling also has
an important role in this disease. In addition, Varjosalo et al.
(2013) have established that active p38 isoforms can interact
with themselves to form positive feedback loops. On the basis
of these observations, we hypothesize that both pathways may
be responsible for increased p38 signaling and p38 levels.
Existing reports of enhanced T-cell activation in both SS and
MF patients (Asadullah et al., 1997; Cire´e et al., 2004) also
support this hypothesis. Sequencing and gene expression
profiling studies that have shown modulated TCR signaling
in CTCL patients and perturbations in the pathway may drive
CTCL malignancy (Hahtola et al., 2006; Vaque´ et al., 2014).
The TCR signaling pathway has been reported to activate the
MAPK signaling pathway (Rinco´n 2001; Makoto and Toshiki
2012) or directly activate p38 through a MAPK-independent
mechanism (Salvador et al., 2005; Ashwell 2006). It is
important to note that CTCL subtypes can express distinct
expression profiles (van Doorn et al., 2009; Vaque´ et al.,
2014); therefore, molecular findings and therapeutic targets
between subtypes may differ. Our observations were made in
SS. Further experimentation on the importance of p38
signaling needs to be performed using models for other
subtypes of CTCL such as MF and the cutaneous CD30þ
T-cell lymphoproliferative disorders.
Using primary information gleaned from our genomic
approaches, such as pathway analysis, we started to explore
downstream signaling members of the p38 cascade. Post
EnzþARA drug treatment, we did not see consistent changes
in the mRNA or protein expression patterns in critical T-cell–
specific downstream p38 signaling members, such as ATF2
and FOS, either mRNA or protein (data not shown). Of note,
FOS was negatively correlated between drug treatment and
patient microarray data sets (Supplementary Table S3 online).
The clinical benefit of inhibiting p38 has been explored for
chronic inflammation associated with chronic obstructive
pulmonary disease, cardiovascular disease, rheumatoid arthri-
tis, nerve pain, and most recently solid tumors (Anand et al.,
2011; ClinicalTrials.gov, 2012; Lukey et al., 2012). Our
observations in CTCL cell lines and patient samples indicate
that p38 may also be a therapeutic target in this disease.
Significant apoptosis was observed in PBMCs isolated from
healthy volunteers, albeit at higher inhibitor concentrations
than required for CTCL cells.
In conclusion, global genomic dissection of gene expression
changes following treatment with inhibitors of key prolifera-
tion pathways in CTCL has identified p38 as a candidate
therapeutic target against this fatal cancer. Additional studies
to elucidate the signaling targets of p38 responsible for cell
death may provide added specificity to this treatment.
MATERIALS AND METHODS
Cell lines and cell culture
Human CTCL SS cell lines H9 and Hut78 were grown as previously
described (Rovedo et al., 2011). For primary samples, Northwestern
institutional review board approval was obtained for this study, and
patients provided written consent. The study was conducted
according to the Declaration of Helsinki Principles. Blood samples
were collected from B2 CTCL patients with 41,000 Se´zary cellsml
 1
(Olsen et al., 2011). Healthy volunteer donors acted as controls.
PBMCs were isolated by ficoll gradient using Histopaque-1077
(Sigma-Aldrich, St Louis, MO) and immediately placed in short-term
drug treatment, complete media with respective compound. Five
patients and five healthy volunteers donated blood.
Small-molecule inhibitors
PKCb inhibitor: Enzastaurin, a gift from Eli Lilly & Company
(Indianapolis, IN); working concentration was 4mM. GSK3 inhibitor:
AR-A014418 (Sigma-Aldrich); working concentration was 5mM. p38
inhibitors: SB202190 (Sigma-Aldrich), SB203580 (EMD Millipore,
Billerica, MA), and BIRB796 (EMD Millipore). All compounds were
dissolved in DMSO (vehicle control). Standard assay conditions for
compound treatment experiments used a 5-day dosing strategy unless
otherwise noted.
Cell death assays
Annexin V/4,6-diamidino-2-phenylindole staining was performed
according to the manufacturer’s directions (BD Biosciences, San Jose,
CA). Cleaved caspase-3/7 and SYTOX positivity were measured using
the CellEvent Caspase-3/7 Green Flow Cytometry Assay Kit (Invitro-
gen, Grand Island, NY) as per the manufacturer’s instructions. Stained
cells were analyzed with the LSRFortessa flow cytometer (BD
Biosciences). These data were analyzed using FlowJo software (Tree
Star, Ashland, OR). To minimize the effects of autofluorescence from
p38 small-molecule inhibitors, Annexin V/DAPI results were gated
using Annexin V versus SSC-A and then presented as percentage of
total cells that were Annexin V positive. A third cell death readout,
poly ADP ribose polymerase cleavage, was measured by immunoblot.
Quantitative real-time reverse-transcriptase–PCR
Total RNA was extracted from cells using the RNeasy Kit (Qiagen,
Valencia, CA). Complementary DNA was synthesized using the
SuperScript Vilo cDNA Synthesis Kit (Invitrogen). Quantitative real-
time reverse-transcriptase–PCR and loading normalization were
performed as previously described (McBrayer et al., 2012). Taqman
gene expression assays used AXIN2, BCL2L1, CD4, CDH1, ICOS,
LAT, MAPK11, MAPK12, MAPK13, MAPK14, and PTPN6 (Applied
Biosystems, Grand Island, NY).
Immunoblotting
Proteins were isolated from cells using cOmplete Lysis M plus
PhosSTOP (Roche, Indianapolis, IN). Immunoblotting was carried
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out as previously described (Rovedo et al., 2011) Quantification was
performed using FujiFilm Multi Gauge software (FujiFilm, Hanover
Park, IL). The following Cell Signaling (Danvers, MA) antibodies were
used: anti-a-tubulin (DM1A), anti-b-actin (8H10D10), anti-p38a
(L53F8), anti-p38b (C28C2), anti-p38g, anti-p38d (10A8), anti-p38–
MAPK, anti-rabbit IgG HRP-linked secondary, and anti-mouse IgG
HRP-linked secondary. Anti-total b-catenin and anti-poly ADP ribose
polymerase antibodies were purchased from EMD Millipore and BD
Biosciences, respectively.
Global gene expression analysis
Gene expression was analyzed in Hut78 cells treated with Enz, ARA,
EnzþARA, DMSO, or with no treatment for 3 days on Illumina
Human HT-12 Expression Bead Chips (n¼ 4; Illumina, San Diego,
CA). Gene expression data were quantile normalized, and drug effect
gene signatures were derived using a t-test between DMSO and the
particular treatment, requesting that Po0.05 and the FC exceeds 2;
we used the R statistical system. All data are publically available at
NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE59179; accession number GSE59179). Gene set enrichment
analysis was performed using the MSigDB gene set collection
(qo0.05) using previously defined methodologies (Subramanian
et al., 2005). A CTCL patient gene signature was generated by
integrating two publicly available gene sets, GSE17602 (28 CTCL
patients; Caprini et al., 2009) and GSE8835 (12 healthy donor CD4þ
samples; Go¨rgu¨n et al., 2005); both data sets were assayed with
Affymetrix HG-U133A Arrays (Affymetrix, Santa Clara, CA), and were
quantile normalized before analysis. Negatively correlated genes
were defined as upregulated FC42 in SS patients and down-
regulated FCo0.5 in drug-treated SS cells, or as downregulated
FCo0.5 in SS patients and upregulated FC42 in drug-treated
SS cells.
Statistics
Data shown are mean±standard deviation (SD). P-values were
calculated using Student’s t-test (paired). Significance: *Pp0.05,
**Pp0.01, and ***Pp0.0001. For BIRB and EnzþARA co-treatment
experiments, mean values (n¼ 3) were normalized to DMSO (BIRB)
treatment values. For each cell line and treatment condition (i.e.,
EnzþARA or no EnzþARA), the mean normalized cell death values
were correlated with the BIRB concentration (Pearson’s correlation),
yielding 18 data points per correlation. Correlations were then
Fisher’s r-to-z transformed to allow a statistical comparison of their
magnitude.
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